Publication:
Exploring Neurodegenerative Diseases: Bridging the Gap Between in Vitro and in Vivo Models

dc.authorscopusid60004295900
dc.authorscopusid41262033500
dc.authorwosidElhaj, Abubaker/Jac-7583-2023
dc.authorwosidOnger, Mehmet/Lfu-5422-2024
dc.contributor.authorEl Elhaj, Abubaker
dc.contributor.authorOnger, Mehmet Emin
dc.contributor.authorIDElhaj, Abubaker Elssidig Elhajbakhit/0000-0002-5359-1823
dc.date.accessioned2025-12-11T01:01:37Z
dc.date.issued2025
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[El Elhaj, Abubaker; Onger, Mehmet Emin] Ondokuz Mayis Univ, Fac Med, Dept Histol & Embryol, Samsun, Turkiyeen_US
dc.descriptionElhaj, Abubaker Elssidig Elhajbakhit/0000-0002-5359-1823;en_US
dc.description.abstractNeurological disorders are brain conditions characterized by the loss of nerve cells, leading to a decline in function. Standard examples include dementia, tremors, involuntary movements, muscle weakness, and autoimmune attacks. The most common form of dementia is Alzheimer's, affecting over 5 million elderly individuals, while tremors, stiffness, and slow movement are caused by Parkinson's. Involuntary movements and emotional problems are caused by Huntington's, while muscle weakness and eventual demise are caused by Amyotrophic lateral sclerosis. Vision problems, fatigue, and difficulty walking are caused by Multiple sclerosis (MS), an autoimmune disease that attacks the myelin sheath. In vitro models provide cost and complexity reduction, environmental control, and high-throughput. Researchers employ both cell-based (in vitro) and animal-based (in vivo) models to investigate neurodegenerative illnesses and endeavor to formulate novel treatments for diverse conditions. In vitro models provide cost and complexity reduction, environment control, and high-throughput screening of potential therapeutic agents compared to in vivo models. Nevertheless, they possess constraints, including the absence of intricate interactions that transpire in the entire organism and the inability to reproduce the disease progression completely.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.2174/0113816128374254250605070049
dc.identifier.issn1381-6128
dc.identifier.issn1873-4286
dc.identifier.pmid40600544
dc.identifier.scopus2-s2.0-105011077998
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.2174/0113816128374254250605070049
dc.identifier.urihttps://hdl.handle.net/20.500.12712/40768
dc.identifier.wosWOS:001530569000001
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Pharmaceutical Designen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDegenerative Diseasesen_US
dc.subjectAlzheimer's Diseaseen_US
dc.subjectParkinson's Diseaseen_US
dc.subjectIn Vivo Modelsen_US
dc.subjectIn Vitro Modelsen_US
dc.subjectImmunological Disordersen_US
dc.titleExploring Neurodegenerative Diseases: Bridging the Gap Between in Vitro and in Vivo Modelsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files